must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 17, 2011.

A. Federal Reserve Bank of Philadelphia (William Lang, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105–1521:

1. Polonia MIC, Huntingdon Valley, Pennsylvania; to convert to stock form and merge with Polonia Bancorp, Inc., Baltimore, Maryland, which proposes to become a savings and loan holding company by acquiring Polonia Bank, Huntingdon Valley, Pennsylvania.

In connection with this application, Polonia Bancorp, Inc., has applied to become a bank holding company.

B. Federal Reserve Bank of Cleveland (Nedine Wallman, Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101–2566:

1. Cheviot Mutual Company, Cheviot, Ohio; to convert to stock form and acquire Cheviot Savings Bank, Cheviot, Ohio. Pursuant to the conversion, Cheviot, Mutual Holding Company and Cheviot Financial Corp., the existing Maryland corporation, has applied to become a wholly owned subsidiary of Cheviot Financial Corp., Huntingdon Valley, Pennsylvania.

In connection with this application, Cheviot Financial Corp., the existing Maryland corporation, has applied to become a bank holding company.

2. Cheviot, Mutual Holding Company, Cheviot, Ohio; to convert to stock form and acquire Cheviot Savings Bank, Cheviot, Ohio. Pursuant to the conversion, Cheviot, Mutual Holding Company and Cheviot Financial Corp., the existing federal mid-tier corporation, will cease to exist, and Cheviot Savings Bank will become a wholly owned subsidiary of Cheviot Financial Corp., Cheviot, Ohio, a Maryland corporation.

In addition, Cheviot Financial Corp., the Maryland corporation, has applied to acquire Cheviot Savings Bank.


Robert deV. Frierson, Deputy Secretary of the Board.

For Further Information Contact:

Diane Cousins, RPh., Center for Quality Improvement and Patient Safety, AHRQ, 540 Gaither Road, Rockville, MD 20850; Telephone (toll free): (866) 403–3697; Telephone (local): (301) 427–1111; TTY (toll free): (866) 438–7231; TTY (local): (301) 427–1130; E-mail: pso@AHRQ.hhs.gov.

SUPPLEMENTARY INFORMATION:

Background

The Patient Safety Act authorizes the listing of PSOs, which are entities or component organizations whose mission and primary activity is to conduct activities to improve patient safety and the quality of health care delivery. HHS issued the Patient Safety Rule to implement the Patient Safety Act. AHRQ administers the provisions of the Patient Safety Act and Patient Safety Rule (PDF file, 450 KB. PDF Help) relating to the listing and operation of PSOs. Section 3.108(d) of the Patient Safety Rule requires AHRQ to provide public notice when it removes an organization from the list of federally approved PSOs.

Patient Safety Organization One, Inc. failed to respond to two findings of deficiency contained in a Notice of Proposed Revocation and Delisting: (1) Failure to provide required notification to AHRQ that the PSO has complied with the requirement of entering into two Patient Safety Act contracts within 24-months of the date of initial listing, as required by 42 U.S.C. 299b–24(b)(1)(C); and (2) failure to submit information necessary for AHRQ to conduct a compliance assessment of the PSO, as required by 42 CFR 3.110.

Patient Safety Organization One, Inc. has not responded to either preliminary notice of deficiency sent by AHRQ pursuant to 42 CFR 3.108(a)(2), nor provided any evidence of a good faith effort to correct either deficiency. Accordingly, pursuant to 42 CFR 3.108(b), AHRQ delisted Patient Safety Organization One, Inc., PSO number P0059, effective at 12:00 Midnight ET (2400) on July 5, 2011.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Patient Safety Organizations: Delisting for Cause of Patient Safety Organization One, Inc.

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Notice of Delisting.

SUMMARY: Patient Safety Organization One, Inc.: AHRQ has delisted Patient Safety Organization One, Inc. as a Patient Safety Organization (PSO) pursuant to 42 CFR 3.108(b). The Patient Safety and Quality Improvement Act of 2005 (Patient Safety Act), Pub. L. 109–41, 42 U.S.C. 299b–21–b–26, provides for the formation of PSOs, which collect, aggregate, and analyze confidential information regarding the quality and safety of health care delivery. The Patient Safety and Quality Improvement Final Rule (Patient Safety Rule), 42 CFR part authorizes AHRQ, on behalf of the Secretary of HHS, to list as a PSO an entity that attests that it meets the statutory and regulatory requirements for listing.

A PSO can be “delisted” by the Secretary if it is found to no longer meet the requirements of the Patient Safety Act and Patient Safety Rule.

DATES: The delisting was effective at 12 Midnight ET (2400) on July 5, 2011.

ADDRESSES: The directories of both listed and delisted PSOs can be accessed electronically at the following HHS Web site: http://www.pso.AHRQ.gov/index.html.

FOR FURTHER INFORMATION CONTACT:

Diane Cousins, RPh., Center for Quality Improvement and Patient Safety, AHRQ, 540 Gaither Road, Rockville, MD 20850; Telephone (toll free): (866) 403–3697; Telephone (local): (301) 427–1111; TTY (toll free): (866) 438–7231; TTY (local): (301) 427–1130; E-mail: pso@AHRQ.hhs.gov.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Patient Safety Organizations: Delisting for Cause of Patient Safety Organization One, Inc.

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Notice of Delisting.

SUMMARY: Patient Safety Organization One, Inc.: AHRQ has delisted Patient Safety Organization One, Inc. as a Patient Safety Organization (PSO) pursuant to 42 CFR 3.108(b). The Patient Safety and Quality Improvement Act of 2005 (Patient Safety Act), Pub. L. 109–41, 42 U.S.C. 299b–21–b–26, provides for the formation of PSOs, which collect, aggregate, and analyze confidential information regarding the quality and safety of health care delivery. The Patient Safety and Quality Improvement Final Rule (Patient Safety Rule), 42 CFR part authorizes AHRQ, on behalf of the Secretary of HHS, to list as a PSO an entity that attests that it meets the statutory and regulatory requirements for listing.

A PSO can be “delisted” by the Secretary if it is found to no longer meet the requirements of the Patient Safety Act and Patient Safety Rule.

DATES: The delisting was effective at 12 Midnight ET (2400) on July 5, 2011.

ADDRESSES: The directories of both listed and delisted PSOs can be accessed electronically at the following HHS Web site: http://www.pso.AHRQ.gov/index.html.

FOR FURTHER INFORMATION CONTACT:

Diane Cousins, RPh., Center for Quality Improvement and Patient Safety, AHRQ, 540 Gaither Road, Rockville, MD 20850; Telephone (toll free): (866) 403–3697; Telephone (local): (301) 427–1111; TTY (toll free): (866) 438–7231; TTY (local): (301) 427–1130; E-mail: pso@AHRQ.hhs.gov.

SUPPLEMENTARY INFORMATION:

Background

The Patient Safety Act authorizes the listing of PSOs, which are entities or component organizations whose mission and primary activity is to conduct activities to improve patient safety and the quality of health care delivery. HHS issued the Patient Safety Rule to implement the Patient Safety Act. AHRQ administers the provisions of the Patient Safety Act and Patient Safety Rule (PDF file, 450 KB. PDF Help) relating to the listing and operation of PSOs. Section 3.108(d) of the Patient Safety Rule requires AHRQ to provide public notice when it removes an organization from the list of federally approved PSOs.

Patient Safety Organization One, Inc. failed to respond to two findings of deficiency contained in a Notice of Proposed Revocation and Delisting: (1) Failure to provide required notification to AHRQ that the PSO has complied with the requirement of entering into two Patient Safety Act contracts within 24-months of the date of initial listing, as required by 42 U.S.C. 299b–24(b)(1)(C); and (2) failure to submit information necessary for AHRQ to conduct a compliance assessment of the PSO, as required by 42 CFR 3.110.

Patient Safety Organization One, Inc. has not responded to either preliminary notice of deficiency sent by AHRQ pursuant to 42 CFR 3.108(a)(2), nor provided any evidence of a good faith effort to correct either deficiency. Accordingly, pursuant to 42 CFR 3.108(b), AHRQ delisted Patient Safety Organization One, Inc., PSO number P0059, effective at 12:00 Midnight ET (2400) on July 5, 2011.
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Guidance for Industry; Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Pistachio-Derived Product as an Ingredient; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance entitled “Guidance for Industry: Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Pistachio-Derived Product as an Ingredient.” The guidance clarifies for manufacturers who produce foods containing a pistachio-derived product as an ingredient that there is a risk that Salmonella species may be present in the incoming pistachio-derived product, and recommends measures to address that risk.

DATES: Submit either electronic or written comments on Agency guidances at any time.

ADRESSES: Submit written requests for single copies of the guidance to the Division of Plant and Dairy Food Safety, Center for Food Safety and Applied Nutrition (HFS–317), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740. Send two self-addressed adhesive labels to assist that office in processing your request. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance.


SUPPLEMENTARY INFORMATION:

I. Background

In the Federal Register of June 29, 2009 (74 FR 31038), FDA announced the availability of a draft guidance entitled “Guidance for Industry: Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Pistachio-Derived Product as an Ingredient” and gave interested parties an opportunity to submit comments by August 28, 2009. The Agency reviewed and evaluated these comments and has modified the guidance where appropriate.

The guidance clarifies for manufacturers who produce foods containing a pistachio-derived product as an ingredient that there is a risk that Salmonella species may be present in the incoming pistachio-derived product, and recommends measures to address that risk. Pistachio-derived products include roasted in-shell pistachios and shelled pistachios (also called kernels) that are roasted or raw. FDA is issuing this guidance as level 1 guidance consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The guidance represents the Agency’s current thinking on measures to address the risk for contamination by Salmonella spp. in food containing a pistachio-derived product as an ingredient. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternate approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

II. Comments

Interested persons may submit to the Division of Dockets Management (see ADDRESSES) either electronic or written comments regarding the guidance. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

III. Electronic Access

Persons with access to the Internet may obtain the guidance at http://www.fda.gov/FoodGuidances or http://www.regulations.gov.